G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $41.38, for a total transaction of $31,035.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of G1 Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $45.30. 541 shares of the company’s stock were exchanged, compared to its average volume of 325,361. G1 Therapeutics Inc has a fifty-two week low of $18.03 and a fifty-two week high of $69.57. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -12.70 and a beta of 1.16.
G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.08. Analysts expect that G1 Therapeutics Inc will post -2.64 earnings per share for the current year.
A number of brokerages recently weighed in on GTHX. BidaskClub raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 3rd. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. Needham & Company LLC reduced their target price on shares of G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Thursday. JPMorgan Chase & Co. upped their target price on shares of G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $74.00.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2018/11/09/jennifer-k-moses-sells-750-shares-of-g1-therapeutics-inc-gthx-stock.html.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.